Slide 1: CB-011, an allogeneic anti-BCMA CAR-T cell therapy with immune cloaking, in r/r multiple myeloma
CB-011, an allogeneic anti-BCMA CAR-T cell therapy with immune cloaking, in patients with relapsed/refractory multiple myeloma Long-term follow-up results from the CaMMouflage phase 1 trial Binod Dhakal, Adriana Rossi, William Clark, Daniel Sherbenou, David Siegel, Manisha Bhutani, Faiz Anwer, Sham
Slide 2: Disclosures
Disclosures Advisory board for Janssen, BMS, Takeda, Sanofi, Pfizer, Genentech, Legend, Karyopharm, Menarini, Kite, Arcellx, AstraZeneca, Caribou, and Natera Institutional funding from Janssen, AstraZeneca, BMS, Sanofi, Pfizer, Arcellx, Kite, C4 Therapeutics, Carsgen, Genmab, Ichnos, and Caribou 2
Slide 3: CB-011 delivering on allogeneic CAR-T promise with high response rates and low infection
CB-011: delivering on the allogeneic CAR-T cell therapy promise with high response rates and low rates of infection for patients with r/r multiple myeloma Bispecifics CB-011 Treatment Repeat dosing Single-dose treatment burden until relapse Weekly or bi-weekly High response rates 2 Efficacy treatmen
Slide 4: CB-011: broad access, rapid treatment, and scalability for r/r multiple myeloma
CB-011: delivering on the allogeneic CAR-T cell therapy promise with broad access, rapid treatment, and scalability for r/r multiple myeloma Bispecifics CB-011 Autologous CAR-T Treatment Repeat dosing Single-dose treatment burden Overcomes access Access 1 of 10 MM patients until relapse challenges t
Slide 5: CB-011: a differentiated allogeneic CAR-T cell therapy for r/r MM
CB-011: a differentiated allogeneic CAR-T cell therapy for r/r MM CB-011 immune cloaking strategy B2M–HLA-E-peptide fusion enhances functional persistence and insertion antitumor activity CB-011 450M cell dose selected as RDE following Manufactured from Anti-BCMA CAR deep, durable responses and heal
Slide 6: CB-011 CaMMouflage phase 1 trial (NCT05722418)
CB-011 CaMMouflage phase 1 trial (NCT05722418) Eligibility Dose escalation • ≥3 prior lines of therapy, including a PI, an IMiD, • LD: 300 mg/m2 cy or 500 mg/m2 cy with 30 mg/m 2 flu x 3 days and an anti-CD38 antibody • CB-011: 50M,150M, 300M, 450M, 800M CAR-T cells • Could have received BCMA-target
Slide 7: High-risk, heavily pretreated patients enrolled in CaMMouflage
High-risk, heavily pretreated patients enrolled in CaMMouflage All patients1 Patient and disease characteristics (N=48) Age, years, median (range) 68.5 (49-84) ≥ 65 years old 32 (67) Male, n (%) 33 (69) ECOG performance status, n (%) 0 13 (27) 1 35 (73) R-ISS disease stage, n (%) at diagnosis I 6 (1
Slide 8: CB-011 induces deep, durable responses in high-risk patients
CB-011 induces deep, durable responses in high-risk patients Heavily pretreated BCMA-naïve patients treated with a single dose of 450M CB-011 CAR-T cells 92% ORR 83% ≥CR rate 91% MRD neg (11/12) (10/12) (10/11 evaluable patients) Patient EMD MRD neg1 Day 28 3 mo 6 mo 9 mo 12 mo 15 mo 18 mo ID (Y/N)
Slide 9: No GvHD, IEC-EC, parkinsonism, or cranial nerve palsies observed
No GvHD, IEC-EC, parkinsonism, or cranial nerve palsies observed All at selected LD1 BCMA-naïve 450M at selected LD1 (N=35) (N=12) Adverse events of special Any grade Grade ≥3 Any grade Grade ≥3 interest n (%) n (%) n (%) n (%) Infections, n (%) 17 (49) 6 (17) 8 (67) 3 (25) CRS, n (%) 12 (34) 1 (3)
Slide 10: Robust CAR-T cell expansion and rapid sFLC decrease correlate with responses
Robust CAR-T cell expansion and rapid sFLC decrease strongly correlate with clinical responses PK at selected LD Rapid sFLC decrease in responders ≥VGPR (N=18) ≥VGPR (N=18) Partial response (N=5) Partial response (N=5) Non-responders (N=12) Absolute number of CAR+ cells/µL Non-responders (N=12) 1 Lo
Slide 11: Balanced central and effector memory CAR+ CD8 T cells support antitumor activity
Balanced central and effector memory CAR+ CD8 T cells support potent antitumor activity and functional persistence CD8 predominance at Cmax CD8 CAR-T memory phenotype at Cmax CD8 CD4 CM EM SCM/ TE naïve Data shown for patients treated with 500mg/m2 cy and 30 mg/m2 flu daily x 3 days at 450M dose. CD
Slide 12: Rapid recovery of endogenous T and NK cells contributes to manageable safety
Rapid recovery of endogenous T and NK cells contributes to the manageable safety profile • Patient T cell depletion enables CAR-T T cells cell expansion • Fast recovery of T and NK cells quickly reinstates the patient’s natural immunity, likely contributing to the NK cells LLOQ B Cells favorable saf
Slide 13: Next steps for CB-011 in r/r MM patients
Next steps for CB-011 in r/r MM patients Enrollment ongoing in dose BCMA-naïve expansion at selected LD with 450M CAR-T cells (RDE) BCMA-exposed 13 RDE: recommended dose for expansion
Slide 14: BCMA-exposed patient case from dose expansion
BCMA-exposed patient case from dose expansion: Ongoing CR following CB-011 in heavily pretreated MM patient who previously received cilta-cel Sex: male Patient received CR observed at Day 28 and Month 3 CB-011 RDE Age: 71 Prior lines of therapy: 8 No CR following any post-1L therapy Dec 2025 Jan 202
Slide 15: Conclusions and next steps for CB-011 in r/r MM patients
Conclusions and next steps for CB-011 in r/r MM patients • Deep and durable responses observed with CB-011 in heavily pre-treated r/r MM patients ✓ 92% ORR, 83% ≥ CR rate, 91% MRD negativity, 50% in ≥CR at 15 months in BCMA-naïve patients treated with the recommended dose for expansion of 450M cells
Slide 16: Gratitude for our patients, caregivers, investigators, and site staff
Gratitude for our patients, caregivers, investigators, and site staff MCW Mt. Sinai MSKCC Cleveland Hackensack Clinic Huntsman OHC VCU U of Colorado Kentucky Tennessee Duke Oncology Levine UAB CaMMouflage trial sites UTSW Miami 16